Rhinosinutab

Quick links to important sections

Rhinosinutab

Method of action: Antitussive, Nasal Preparations

Treatment option: Rhinitis, Hay Fever

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rhinosinutab

What Type of Medicine is Rhinosinutab?

Rhinosinutab is a synthetic, fixed-dose combination product prepared as an oral tablet. It is classified as a combined systemic antihistamine and decongestant. This preparation is characterized by a dual-action profile intended to address both allergic and congestive symptoms simultaneously. As a multicomponent preparation, it combines two pharmacologically distinct entities into a single dosage form for systemic action, offering an integrated approach to managing the discomfort of upper respiratory issues. Formulations containing this specific fixed-dose combination are utilized by those seeking a single tablet solution for symptom management.


Composition: Cetirizine Hydrochloride and Pseudoephedrine

The two active ingredients that constitute Rhinosinutab are Cetirizine Hydrochloride and Pseudoephedrine, both of synthetic origin. Cetirizine Hydrochloride functions as a second-generation H1-antagonist, which works by mitigating the body's allergic response through selective peripheral H1-receptor blockade. This antihistamine component is used for the management of symptoms such as sneezing and itching. Pseudoephedrine serves as the sympathomimetic component, specifically targeting vasoconstriction of mucosal blood vessels to address physical congestion. The preparation is a complementary formulation designed to provide the combined effects of its components through a single oral preparation.


General Purpose and Benefit of the Combination

The primary purpose of Rhinosinutab is to provide relief by addressing the underlying allergic trigger and the resulting physical obstruction. This dual action is intended for scenarios where individuals experience sino-nasal congestion alongside symptoms of allergic rhinitis or other forms of vasomotor rhinitis. By combining an antihistamine with a systemic decongestant, the preparation aims to reduce tissue swelling (edema) and mitigate the allergic cascade, providing a singular approach to relieving upper respiratory tract congestion.

What side effects are possible with Rhinosinutab?

Possible side effects and safety information

Rhinosinutab, the combination of Cetirizine and Pseudoephedrine, has a safety profile defined by regulatory bodies (such as the FDA and EMA) through classification of observed adverse reactions. These effects are grouped by their incidence frequency and the body systems they impact, reflecting the dual nature of the medicine.

Frequency-Classified Adverse Reactions

Adverse events are formally classified based on the observed frequency in clinical studies and post-marketing reports:

  • Common: Events reported relatively frequently, including Somnolence (drowsiness), Fatigue, Dry Mouth, Headache, Insomnia, and Dizziness.
  • Rare: Infrequently reported events like Hypersensitivity reactions, Convulsions, Tachycardia (rapid heart rate), and Arrhythmia.
  • Very Rare: Extremely rare events such as Anaphylactic Shock and Angioneurotic Oedema.

System-Organ Classes and Serious Safety Notes

The most commonly affected areas are the Nervous System (somnolence, headache), Psychiatric Disorders (insomnia, nervousness), and Gastrointestinal Disorders (dry mouth, nausea). Serious adverse reactions explicitly documented in regulatory safety data include Anaphylactic Shock and the post-marketing report of Ischaemic Optic Neuropathy.

Population-Specific Constraints

Official labeling mandates specific safety considerations for certain populations. The medicine requires caution and potential adjustment in patients with Renal or Hepatic Impairment due to reduced clearance of its components. Older Adults may be more sensitive to adverse effects. The product is also subject to restrictions, including being contraindicated in patients with pre-existing conditions such as Severe Hypertension, Severe Coronary Artery Disease, Narrow-Angle Glaucoma, or Urinary Retention.

Certain effects, like severe itching (Pruritus) after stopping long-term use of the Cetirizine component, are specifically noted in regulatory safety communications as duration-related patterns.

Overdose and Emergency Response

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations: Overdose manifests through combined effects, including CNS signs such as somnolence, excitement, confusion, and tremor. Gastrointestinal signs like diarrhea and abdominal pain are also listed.
Physiological systems affected (as stated in label): Primarily the Central Nervous System and Cardiovascular System. Cardiovascular signs include tachycardia, irregular heartbeat, and increased blood pressure.
Population-specific overdose notes (if applicable): The pediatric population has an increased risk of significant CNS effects. Patients with uncontrolled hypertension or severe kidney failure face a documented heightened risk of serious cerebrovascular events.
Emergency-response statements (as written in official documents): Management is defined as symptomatic and supportive treatment. Procedures such as gastric lavage may be considered. There is no known specific antidote.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents): The profile covers effects ranging from common overdose manifestations to potentially life-threatening complications, including convulsions and specific cerebrovascular syndromes.
When immediate medical help is required (label-derived phrasing only): Requires seeking immediate medical attention for suspected overdose. Stop use immediately and seek urgent medical assistance if symptoms like a sudden, severe headache, confusion, seizures, or visual changes develop.

Resulting Overdose Structure

Official overdose statements:

  • Immediate medical attention is required when an overdose is suspected or if severe manifestations such as seizures or hallucinations occur.
  • The Pseudoephedrine component carries the documented risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS).

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile by listing the expected clinical manifestations, which range from CNS and GI signs to severe neurological and cardiovascular events. This profile dictates the mandated emergency response, explicitly requiring patients to seek immediate medical attention for any suspected overdose. Management is reliant on symptomatic and supportive treatment, a necessity stemming from the official note that no specific antidote is known for a key component.

Therapeutic Uses of Rhinosinutab

What Rhinosinutab Treats: Main Uses and Benefits

Rhinosinutab is commonly used for the symptomatic relief of allergic rhinitis, a condition characterized by periods of heightened symptoms due to airborne triggers such as pollen, dust, and pet dander. The medication is applied in addressing symptom clusters that may become intense or disruptive, including persistent sneezing, itchy eyes and throat, and a bothersome runny nose (rhinorrhea). Providing this systemic support is intended to help ease the overall burden of symptoms, generally contributing to improved comfort during periods of heightened symptoms.

The primary indications include symptomatic management of seasonal allergic rhinitis, perennial allergic rhinitis, and temporary relief of congestion associated with upper respiratory viral infections like the common cold or flu. The medication is specifically applied to address the related problem of nasal and sinus congestion. This is relevant in clinical settings marked by physical obstruction, where symptoms include a stuffy nose and the discomfort of sinus pressure.

The therapeutic benefit is centered on helping to ease the physical discomfort of blockage, which supports general well-being during symptomatic phases. It provides supportive relief that is often used when symptoms intensify and symptomatic assistance is needed.

“The supportive therapeutic benefit is relevant when symptoms related to inflammatory or irritative states occur alongside physical nasal blockage.”


Quick Fact: Relief for Dual Symptom Manifestations

Regulatory References

  1. DailyMed overview of the combination's uses

Eligibility and Restrictions for Use

Eligibility and Contraindications for Rhinosinutab Use

Rhinosinutab (Cetirizine/Pseudoephedrine combination) use is strictly defined by regulatory guidelines based on age, existing medical conditions, and physiological status. The medicine is typically established for use in Adults and Children 12 years of age and over who do not have any restricting conditions. Use is not recommended for the tablet formulation in children under 12 years of age or for women who are breastfeeding.

Absolute Contraindications mean the medicine must not be used under any circumstances. This includes patients with a known hypersensitivity to any component, those currently taking or having recently stopped a Monoamine Oxidase Inhibitor (MAOI), or those with severe high blood pressure (hypertension) or severe coronary artery disease. Use is also contraindicated in patients with narrow-angle glaucoma or severe renal impairment.

Conditional Restrictions apply to other patient groups who must consult a healthcare professional before use. This includes adults 65 years and over, pregnant women, and patients with non-severe heart disease, diabetes, or thyroid disease. Patients with milder liver or kidney disease or those with prostate enlargement should also seek professional guidance.

What should I know about interactions with other medicines?

The interaction profile of Rhinosinutab, a fixed-dose combination of Cetirizine and Pseudoephedrine, is strictly defined by regulatory prohibitions and specific alterations to drug disposition. The interactions are classified based on official documentation.

Prohibited Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the risk of severe hypertensive reactions. The label includes a mandatory timing separation requirement that this product must not be used within 14 days of discontinuing MAOI therapy. Combinations with Hydroxyzine and specific Ergot Derivatives (vasoconstrictive CYP3A4 substrates) are also classified as explicitly contraindicated by regulatory bodies.

Pharmacodynamic and Clearance Alterations

Co-use with alcohol or other Central Nervous System (CNS) Depressants results in additive pharmacodynamic effects, increasing the potential for drowsiness. Use alongside other Sympathomimetic Agents may also increase the documented risk of adverse cardiovascular effects due to additive stimulation. A specific pharmacokinetic interaction involves Theophylline (400 mg once daily), which decreases the clearance of Cetirizine by 16%, thereby modifying its exposure. Alkalinizing Agents may increase the serum concentration of the Pseudoephedrine component.

Population and Substance Constraints

Official data documents reduced clearance and increased exposure of Cetirizine in patients with hepatic impairment. The use of the decongestant component is restricted in individuals with severe acute or chronic kidney failure due to its reduced elimination. Intake of caffeine-containing foods or beverages should be limited due to the potential for additive stimulant effects.

Mechanism of Action

The mechanism of Rhinosinutab involves the synergistic action of two components targeting distinct physiological systems: histamine-mediated signaling and sympathetic vascular regulation.


Modulating the Histaminergic System

This domain describes the action of Cetirizine, a component that functions as a selective inverse agonist or antagonist at peripheral histamine H1 receptors. This interaction suppresses the signaling sequences typically initiated by endogenous histamine, a key inflammatory mediator. The resulting reduction in H1 receptor activation affects downstream molecular processes, limiting histamine's influence on increased vascular permeability and sensory nerve stimulation.


Regulating Vascular Tone in Mucosa

This mechanism is mediated by Pseudoephedrine, which primarily acts as an agonist on alpha-adrenergic receptors within the microvasculature of the nasal and sinus lining. This alpha-adrenergic engagement initiates signal transduction pathways that regulate local smooth muscle contraction, inducing vasoconstriction. The resulting vasoconstriction directly reduces localized mucosal blood volume and the extravasation of plasma, which consequently modulates the physiological state of the tissues.

Dosage and Administration Information

How to Use Rhinosinutab

Rhinosinutab is used exclusively via the oral route of administration as an extended-release tablet containing 5 mg of Cetirizine Hydrochloride and 120 mg of Pseudoephedrine Hydrochloride per unit. The established usage pattern is intended to maintain consistent systemic relief for the duration specified in the product labeling.


Standard Dosing and Administration

Feature Official Use Pattern (Adults ge 12 Years)
Standard Dose One tablet
Frequency Every 12 hours (Twice Daily)
Maximum Dose Two tablets per 24 hours
Intake Condition May be taken with or without food

Administration requires specific handling to preserve the extended-release mechanism of the tablet. The dose must be swallowed whole and must not be broken, crushed, or chewed. This method is intended to facilitate the gradual release of the active ingredients over the 12-hour period. The duration of use is typically short-term and symptom-dependent, intended for temporary relief.


Population-Specific Adjustments

Dose modifications are specified for certain patient groups to prevent potential accumulation of the active ingredients. For individuals 65 years of age and older, as well as those with renal (kidney) or hepatic (liver) impairment, the standard usage pattern is adjusted. In these cases, a reduced dose of one tablet once daily may be required. The product is not recommended for use in children under 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rhinosinutab

This overview summarizes the available research used to evaluate the combination of cetirizine and pseudoephedrine, focusing only on the types of clinical studies conducted and the general patterns they described, consistent with official regulatory evidence.


Evidence for Use in Seasonal Allergic Rhinitis

The core evidence relevant to the evaluation of this combination in seasonal allergic rhinitis (SAR) comes from short- to medium-term, randomized controlled trials. These are studies where participants were randomly assigned to receive either the medicine, a placebo (dummy pill), or one of the active ingredients alone, often in a double-blind setting.

Research mainly examined how symptoms change over time during specific allergy seasons. The primary measurement used in these trials was a Total Nasal Symptom Score (TNSS), a composite tool used in studies examining symptom intensity or variability. Studies reported how symptoms evolved in the observed populations, noting patterns related to symptom score changes when using the combination versus the use of placebo or the individual components.


Evidence for Use in Perennial Allergic Rhinitis

The research for perennial allergic rhinitis (PAR), a condition involving periods of heightened symptoms that occur year-round, often utilized study designs similar to those for SAR. Research exploring symptom patterns that occur year-round examined continuous symptom management in individuals with year-round triggers such as dust mites or pet dander. These studies report how symptoms evolved in the observed populations over short periods, usually no longer than a few weeks.

Limited information for long-term outcomes is a key limitation in this area. Since PAR is a chronic condition, the duration of key efficacy trials was limited, meaning that data for extended, continuous use over many months are not fully established.


Evidence for Nasal and Sinus Congestion

Studies evaluated symptoms of nasal obstruction and associated sinus pressure, which are outcomes related to physical discomfort. The evidence primarily comes from brief, controlled trials, including some studies that employed objective methods, such as rhinomanometry (which quantifies nasal airflow), alongside patient self-reported scores for nasal obstruction.

Studies explored short-term symptom changes, often observing responses over defined time intervals shortly after taking the dose. Studies explored whether observed changes in congestion scores and objective airflow measurements differed when the combination was used compared to the antihistamine component alone.

Key Studies & References

  1. A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis
  2. Label: CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE tablet, film coated, extended release (Authoritative Regulatory Labelling)

Frequently Asked Questions (FAQ)

Common questions about Rhinosinutab (FAQ)


Q: Is Rhinosinutab an antibiotic?

A: No, Rhinosinutab is not classified as an antibiotic. Official drug information defines this medicine as a combination of a systemic antihistamine and a decongestant. It is intended to relieve allergy symptoms and congestion, not to treat bacterial infections.

Q: Does Rhinosinutab help with nasal congestion only?

A: Rhinosinutab is officially indicated for more than just nasal congestion. Regulatory documents state it is used for symptoms associated with allergic rhinitis, which typically includes congestion alongside symptoms like sneezing, runny nose, and itching.

Q: Can I take Rhinosinutab if I only have a headache?

A: Regulatory indications describe the intended use of Rhinosinutab for symptoms linked to allergic rhinitis and nasal congestion. Headache is not listed as a primary indication for using this medicine alone. The product is designed to treat the combined symptoms of congestion and allergy.

Q: What is the main difference between Rhinosinutab and a standard cold medicine?

A: Rhinosinutab is defined as a specific fixed-dose combination containing a second-generation antihistamine (Cetirizine) and a decongestant (Pseudoephedrine). While some cold medicines share these components, this specific combination is classified by its unique dual-action profile for allergy and congestion, according to official labeling.

Q: Can I drink coffee or tea while using Rhinosinutab?

A: Official warnings advise that the intake of caffeine-containing foods or beverages, such as coffee or tea, should be limited while using Rhinosinutab. This caution is in place due to the potential for additive stimulating effects from both the caffeine and the decongestant component of the medicine.

Q: Does Rhinosinutab cause rebound congestion?

A: Rebound congestion (a worsening of symptoms after stopping use) is mainly associated with the overuse of topical nasal sprays. Regulatory documents for this oral Pseudoephedrine combination generally do not list this specific effect as a standard risk.

Q: What should I do if I forget to take a dose of Rhinosinutab?

A: Official patient information often describes a usage pattern where the missed dose may be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. The typical pattern described is that the missed dose is skipped. Official usage guidance specifies that extra medicine should not be taken to make up for a missed dose.

Q: Can Rhinosinutab affect my blood pressure?

A: Yes, regulatory warnings note that the pseudoephedrine component is a vasoconstrictor that can potentially affect blood pressure. Because of this, the medicine is strictly contraindicated in patients with severe, uncontrolled high blood pressure (hypertension), as an increase in blood pressure can occur.

Q: Are there studies showing how well Rhinosinutab works for sinus pain?

A: Clinical studies supporting the use of Rhinosinutab have primarily focused on measuring changes in sinus pressure and nasal obstruction related to congestion and allergy. While it treats these symptoms, 'sinus pain' is not typically listed as a primary measurement or outcome in the official research evidence.

Q: Does Rhinosinutab affect fertility?

A: Official regulatory documents include sections on reproductive health. However, information regarding the effects of the active ingredients on human fertility is often not established or limited in the available safety data.

Q: Is Rhinosinutab available without a prescription?

A: Products with the specific concentration of active ingredients in Rhinosinutab (Cetirizine/Pseudoephedrine) are commonly approved by regulatory agencies for use as an Over-The-Counter (OTC) medication, meaning they are generally available without a prescription for temporary relief.

Q: How does the mechanism of action differ from a nasal spray for congestion?

A: Rhinosinutab works as a systemic decongestant, meaning the active ingredient is absorbed into the bloodstream and works internally to constrict vessels throughout the nasal passages. In contrast, most nasal sprays for congestion work locally by applying the medicine directly to the nasal lining.

Q: Is Rhinosinutab a brand name or a generic name?

A: Rhinosinutab is considered a brand name designated for a specific product. However, the active ingredients themselves, Cetirizine and Pseudoephedrine, are the generic components that may be used in various products manufactured by different companies.

Q: Is it normal to feel a bit sleepy after taking Rhinosinutab?

A: Yes, official safety information lists Somnolence, or drowsiness, as a Common adverse reaction. This indicates that feeling slightly sleepy is an expected effect reported relatively frequently by people using the medicine.

Q: Can I drive or operate machinery after taking Rhinosinutab?

A: Regulatory warnings caution that the medicine may impair thinking or reactions due to the potential for drowsiness. Regulatory warnings suggest caution is necessary when performing tasks requiring mental alertness, such as operating machinery or driving.

Q: Can I take Rhinosinutab with vitamins or herbal supplements?

A: Official information suggests consulting with a healthcare professional before combining the drug with any other products, including vitamins and herbal products. This is due to the potential for unknown interactions that are not always listed in the core drug documents.

Q: If I am taking medication for depression, can I use Rhinosinutab?

A: Official labeling contains a strict contraindication regarding use with Monoamine Oxidase Inhibitors (MAOIs), which are a class of antidepressant. The medicine is not for use within 14 days of discontinuing MAOI therapy, as described in the official contraindications.

Q: Are the side effects of Rhinosinutab reversible?

A: The side effects listed in regulatory documents (such as dry mouth and drowsiness) are generally related to the presence of the drug in the body. This profile suggests that most common effects are typically reversible and subside after the medicine is discontinued.

Q: Can taking Rhinosinutab make me feel anxious or jittery?

A: Yes, the official adverse reactions list includes effects like Nervousness and Insomnia (difficulty sleeping). These are common reactions in the Psychiatric Disorders category and may be perceived by the user as feeling jittery or anxious.

How should Rhinosinutab be stored and disposed of?

How to Store and Dispose of Rhinosinutab?

Regulatory documents outline specific requirements for the storage and disposal of Rhinosinutab (Cetirizine Hydrochloride and Pseudoephedrine) to maintain its stability and ensure public safety.

Storage Requirement Rule
Temperature Store at controlled room temperature, 20 C to 25 C.
Environment Keep away from excessive heat, moisture, and direct light; do not freeze.
Container Keep in the original container, tightly closed. Do not use if the seal is torn.
Child Safety Mandatory to keep out of the sight and reach of children.

For disposal, the official method is utilizing a drug take-back program or mail-back envelope. If this option is unavailable, the unused medicine must be mixed with an unappealing substance, sealed in a plastic bag, and placed in household trash. It is strictly prohibited to flush the tablets down the toilet or discard them in any wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rhinosinutab found in:

A-Z Index: